Differential Sensitivity of ERBB2 Kinase Domain Mutations Towards Lapatinib

PLoS ONE - United States
doi 10.1371/journal.pone.0026760
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Combining Lapatinib (GW572016), a Small Molecule Inhibitor of ErbB1 and ErbB2 Tyrosine Kinases, With Therapeutic Anti-ErbB2 Antibodies Enhances Apoptosis of ErbB2-overexpressing Breast Cancer Cells

Oncogene
Cancer ResearchGeneticsMolecular Biology
2005English

ErbB2 Inhibition by Lapatinib Promotes Degradation of Mutant P53 Protein in Cancer Cells

Oncotarget
Oncology
2016English

P2.13-46 Comprehensive Investigation of ERBB2 Transmembrane Domain Mutations (V659/G660) in 12,833 Chinese Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Disease-Associated Mutations in Conserved Residues of ALK-1 Kinase Domain

European Journal of Human Genetics
Genetics
2003English

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated With Lapatinib Resistance and Neoplastic Transformation

Clinical Cancer Research
Cancer ResearchOncology
2008English

Figure 1: Overview of the Kinase Domain of Mps1 and Point Mutations.

English

Targeting Oncoprotein Stability Overcomes Drug Resistance Caused by FLT3 Kinase Domain Mutations

PLoS ONE
Multidisciplinary
2014English

EGFR Kinase Domain Mutations – Functional Impact and Relevance for Lung Cancer Therapy

Oncogene
Cancer ResearchGeneticsMolecular Biology
2007English

Outcome of Patients With Chronic Myeloid Leukemia With Multiple ABL1 Kinase Domain Mutations Receiving Tyrosine Kinase Inhibitor Therapy

Haematologica
Hematology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy